{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:12:43Z","timestamp":1790802763025,"version":"4.1.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T00:00:00Z","timestamp":1566604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The latest estimate of the prevalence of inflammatory bowel disease (IBD) in the United States was based on 2009 data, which indicates a need for an up-to-date re-estimation. The objectives of this study were to investigate the prevalence of all forms of IBD including ulcerative colitis (UC), Crohn\u2019s disease (CD), and IBD unspecified (IBDU).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pediatric (age 2\u201317) and adult (age \u226518) IBD patients were identified from 2 large claims databases. For each year between 2007 and 2016, prevalence was calculated per 100,000 population and standardized based on the 2016 national Census. A fixed-effects meta-analytical model was used for overall prevalence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The pediatric prevalence of IBD overall increased by 133%, from 33.0\/100,000 in 2007 to 77.0\/100,000 in 2016. Among children, CD was twice as prevalent as UC (45.9 vs 21.6). Prevalence was higher in boys than girls for all forms of IBD, in contrast to the adult population where the prevalence was higher in women than men. We also found that the 10\u201317 age subgroup was the major contributor to the rising pediatric IBD prevalence. For adults, the prevalence of IBD overall increased by 123%, from 214.9 in 2007 to 478.4 in 2016. The prevalence rates of UC and CD were similar (181.1 vs 197.7) in 2016.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Inflammatory bowel disease continues to affect a substantial proportion of the US population. In 2016, 1 in 209 adults and 1 in 1299 children aged 2\u201317 were affected by IBD. Prevalence of IBD has been increasing compared with previously published 2009 data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izz182","type":"journal-article","created":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T19:24:24Z","timestamp":1566588264000},"source":"Crossref","is-referenced-by-count":84,"title":["Prevalence of Inflammatory Bowel Disease in Pediatric and Adult Populations: Recent Estimates From Large National Databases in the United States, 2007\u20132016"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9090-9431","authenticated-orcid":false,"given":"Yizhou","family":"Ye","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar","family":"Manne","sequence":"additional","affiliation":[{"name":"Department of Safety & Observational Statistics, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R","family":"Treem","sequence":"additional","affiliation":[{"name":"Clinical Science, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Bennett","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,24]]},"reference":[{"key":"2019091012402742500_CIT0001","author":"United States Centers for Disease Control and Prevention"},{"key":"2019091012402742500_CIT0002","unstructured":"Crohn\u2019s and Colitis Foundation of America. The facts about inflammatory bowel diseases. http:\/\/www.crohnscolitisfoundation.org\/assets\/pdfs\/updatedibdfactbook.pdf Published 2014. Updated November 2014. Accessed September 12, 2018."},{"key":"2019091012402742500_CIT0003","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/jcp.2003.015214","article-title":"Indeterminate colitis","volume":"57","author":"Guindi","year":"2004","journal-title":"J Clin Pathol."},{"key":"2019091012402742500_CIT0004","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology."},{"key":"2019091012402742500_CIT0005","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11938-018-0173-3","article-title":"The natural history of IBD: lessons learned","volume":"16","author":"Weimers","year":"2018","journal-title":"Curr Treat Options Gastroenterol."},{"key":"2019091012402742500_CIT0006","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1053\/j.gastro.2008.09.012","article-title":"Direct health care costs of Crohn\u2019s disease and ulcerative colitis in US children and adults","volume":"135","author":"Kappelman","year":"2008","journal-title":"Gastroenterology."},{"key":"2019091012402742500_CIT0007","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1067\/S0022-3476(03)00444-X","article-title":"Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study","volume":"143","author":"Kugathasan","year":"2003","journal-title":"J Pediatr."},{"key":"2019091012402742500_CIT0008","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1053\/j.gastro.2008.06.081","article-title":"Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease","volume":"135","author":"Van Limbergen","year":"2008","journal-title":"Gastroenterology."},{"key":"2019091012402742500_CIT0009","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jpeds.2004.08.043","article-title":"Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry","volume":"146","author":"Heyman","year":"2005","journal-title":"J Pediatr."},{"key":"2019091012402742500_CIT0010","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/MPG.0b013e3181596efd","article-title":"Natural history of paediatric inflammatory bowel diseases over a 5-year follow-up: a retrospective review of data from the register of paediatric inflammatory bowel diseases","volume":"46","author":"Newby","year":"2008","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"2019091012402742500_CIT0011","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10620-012-2371-5","article-title":"Recent trends in the prevalence of Crohn\u2019s disease and ulcerative colitis in a commercially insured US population","volume":"58","author":"Kappelman","year":"2013","journal-title":"Dig Dis Sci."},{"key":"2019091012402742500_CIT0012","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jpeds.2010.02.024","article-title":"Incidence, prevalence, and time trends of pediatric inflammatory bowel disease in Northern California, 1996 to 2006","volume":"157","author":"Abramson","year":"2010","journal-title":"J Pediatr."},{"key":"2019091012402742500_CIT0013","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1111\/j.1572-0241.2008.01960.x","article-title":"Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002","volume":"103","author":"Herrinton","year":"2008","journal-title":"Am J Gastroenterol."},{"key":"2019091012402742500_CIT0014","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/j.1365-2036.2011.04628.x","article-title":"The changing pattern of Crohn\u2019s disease incidence in northern France: a continuing increase in the 10- to 19-year-old age bracket (1988-2007)","volume":"33","author":"Chouraki","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"key":"2019091012402742500_CIT0015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1471-230X-12-79","article-title":"13-year mortality trends among hospitalized patients with inflammatory bowel disease","volume":"12","author":"Sewell","year":"2012","journal-title":"BMC Gastroenterol."},{"key":"2019091012402742500_CIT0016","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2018","journal-title":"Lancet."},{"key":"2019091012402742500_CIT0017","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/ajg.2017.97","article-title":"Trends in epidemiology of pediatric inflammatory bowel disease in Canada: distributed network analysis of multiple population-based provincial health administrative databases","volume":"112","author":"Benchimol","year":"2017","journal-title":"Am J Gastroenterol."},{"key":"2019091012402742500_CIT0018","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.crohns.2013.01.010","article-title":"The burden of inflammatory bowel disease in Europe","volume":"7","author":"Burisch","year":"2013","journal-title":"J Crohns Colitis."},{"key":"2019091012402742500_CIT0019","first-page":"704","article-title":"Update on the incidence and prevalence of inflammatory bowel disease in the United States","volume":"12","author":"Loftus","year":"2016","journal-title":"Gastroenterol Hepatol (N Y)."},{"key":"2019091012402742500_CIT0020","doi-asserted-by":"crossref","first-page":"190","DOI":"10.15585\/mmwr.mm6706a4","article-title":"Health-risk behaviors and chronic conditions among adults with inflammatory bowel disease - United States, 2015 and 2016","volume":"67","author":"Xu","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"2019091012402742500_CIT0021","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.cgh.2016.10.039","article-title":"Incidence and prevalence of Crohn\u2019s disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010","volume":"15","author":"Shivashankar","year":"2017","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2019091012402742500_CIT0022","author":"Truven Health Analytics"},{"key":"2019091012402742500_CIT0023","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1155\/2012\/278495","article-title":"Development and validation of an administrative case definition for inflammatory bowel diseases","volume":"26","author":"Rezaie","year":"2012","journal-title":"Can J Gastroenterol."},{"key":"2019091012402742500_CIT0024","unstructured":"Ye\n              Y\n            , ManneS, BennettD. Identifying IBD patients in claims database: a comparison of validated algorithms. Post presented at the 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE); Prague, Czech Republic; August 2018.+"},{"key":"2019091012402742500_CIT0025","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1183\/13993003.01945-2015","article-title":"Inflammatory bowel disease and risk of mortality in COPD","volume":"47","author":"Vutcovici","year":"2016","journal-title":"Eur Respir J."},{"key":"2019091012402742500_CIT0026","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-230X-14-140","article-title":"Decreasing incidence of inflammatory bowel disease in eastern Canada: a population database study","volume":"14","author":"Leddin","year":"2014","journal-title":"BMC Gastroenterol."},{"key":"2019091012402742500_CIT0027","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/apt.12873","article-title":"The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study","volume":"40","author":"Reich","year":"2014","journal-title":"Aliment Pharmacol Ther."},{"key":"2019091012402742500_CIT0028","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1038\/ajg.2014.313","article-title":"Oral corticosteroids and the risk of serious infections in patients with elderly-onset inflammatory bowel diseases","volume":"109","author":"Brassard","year":"2014","journal-title":"Am J Gastroenterol."},{"key":"2019091012402742500_CIT0029","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/DCR.0000000000000003","article-title":"Infliximab in ulcerative colitis: the impact of preoperative treatment on rates of colectomy and prescribing practices in the province of British Columbia, Canada","volume":"57","author":"Moore","year":"2014","journal-title":"Dis Colon Rectum."},{"key":"2019091012402742500_CIT0030","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/ajg.2016.106","article-title":"Ulcerative colitis patients with Clostridium difficile are at increased risk of death, colectomy, and postoperative complications: a population-based inception cohort study","volume":"111","author":"Negr\u00f3n","year":"2016","journal-title":"Am J Gastroenterol."},{"key":"2019091012402742500_CIT0031","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s11605-017-3530-y","article-title":"Incidence rates and predictors of colectomy for ulcerative colitis in the era of biologics: results from a provincial database","volume":"22","author":"Abou Khalil","year":"2018","journal-title":"J Gastrointest Surg."},{"key":"2019091012402742500_CIT0032","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ibd.21493","article-title":"Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification","volume":"17","author":"Levine","year":"2011","journal-title":"Inflamm Bowel Dis."},{"key":"2019091012402742500_CIT0033","author":"Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER)"},{"key":"2019091012402742500_CIT0034","author":"Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER)"},{"key":"2019091012402742500_CIT0035","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/(SICI)1097-0258(19970415)16:7<791::AID-SIM500>3.0.CO;2-#","article-title":"Confidence intervals for directly standardized rates: a method based on the gamma distribution","volume":"16","author":"Fay","year":"1997","journal-title":"Stat Med."},{"key":"2019091012402742500_CIT0036","volume-title":"Meta-analysis: fixed effect vs. random effects","author":"Borenstein","year":"2007"},{"key":"2019091012402742500_CIT0037","first-page":"1221","article-title":"Observational studies of drug safety in multi-database studies: methodological challenges and opportunities","volume":"4","author":"Platt","year":"2016","journal-title":"EGEMS (Wash DC)."},{"key":"2019091012402742500_CIT0038","author":"The United States Census Bureau"},{"key":"2019091012402742500_CIT0039","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/ajg.2011.44","article-title":"Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature","volume":"106","author":"Hou","year":"2011","journal-title":"Am J Gastroenterol."},{"key":"2019091012402742500_CIT0040","first-page":"511","article-title":"Diet and inflammatory bowel disease","volume":"11","author":"Knight-Sepulveda","year":"2015","journal-title":"Gastroenterol Hepatol (N Y)."},{"key":"2019091012402742500_CIT0041","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/MIB.0000000000000852","article-title":"Environmental hygiene and risk of inflammatory bowel diseases: a systematic review and meta-analysis","volume":"22","author":"Cholapranee","year":"2016","journal-title":"Inflamm Bowel Dis."},{"key":"2019091012402742500_CIT0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.crohns.2013.10.006","article-title":"Differences in the management of pediatric and adult onset ulcerative colitis\u2014lessons from the joint ECCO and ESPGHAN consensus guidelines for the management of pediatric ulcerative colitis","volume":"8","author":"Ruemmele","year":"2014","journal-title":"J Crohns Colitis."},{"key":"2019091012402742500_CIT0043","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1111\/j.1572-0241.2006.00603.x","article-title":"The epidemiology of inflammatory bowel disease in Canada: a population-based study","volume":"101","author":"Bernstein","year":"2006","journal-title":"Am J Gastroenterol."},{"key":"2019091012402742500_CIT0044","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.gastro.2016.10.020","article-title":"Understanding and preventing the global increase of inflammatory bowel disease","volume":"152","author":"Kaplan","year":"2017","journal-title":"Gastroenterology."},{"key":"2019091012402742500_CIT0045","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1097\/01.MIB.0000436957.77533.b2","article-title":"Association of circulating vitamin D concentrations with intestinal but not systemic inflammation in inflammatory bowel disease","volume":"19","author":"Garg","year":"2013","journal-title":"Inflamm Bowel Dis."},{"key":"2019091012402742500_CIT0046","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/1751-2980.12567","article-title":"Inadequate sunlight exposure in patients with inflammatory bowel disease","volume":"19","author":"Vernia","year":"2018","journal-title":"J Dig Dis."},{"key":"2019091012402742500_CIT0047","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/ibd.22986","article-title":"Systematic review: the role of race and socioeconomic factors on IBD healthcare delivery and effectiveness","volume":"19","author":"Sewell","year":"2013","journal-title":"Inflamm Bowel Dis."},{"key":"2019091012402742500_CIT0048","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.mcna.2009.10.002","article-title":"Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD","volume":"94","author":"Sauer","year":"2010","journal-title":"Med Clin North Am."},{"key":"2019091012402742500_CIT0049","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.cgh.2007.07.012","article-title":"The prevalence and geographic distribution of Crohn\u2019s disease and ulcerative colitis in the United States","volume":"5","author":"Kappelman","year":"2007","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2019091012402742500_CIT0050","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12871-015-0165-y","article-title":"Codifying healthcare\u2014big data and the issue of misclassification","volume":"15","author":"Ladha","year":"2015","journal-title":"BMC Anesthesiol."},{"key":"2019091012402742500_CIT0051","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/ibd.20021","article-title":"Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings","volume":"13","author":"Herrinton","year":"2007","journal-title":"Inflamm Bowel Dis."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izz182\/29207466\/izz182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T09:36:45Z","timestamp":1569231405000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article\/doi\/10.1093\/ibd\/izz182\/5554163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,24]]},"references-count":51,"URL":"https:\/\/doi.org\/10.1093\/ibd\/izz182","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,24]]},"article-number":"izz182"}}